September 2007 -- The law firm Merchant Law Group LLP is investigating a class action against Health Canada for the use of injections containing gadolinium for magnetic resonance imaging ('MRI') and magnetic resonance angiograsphy ('MRA')

The United State's Food and Drug Administration has linked the use of gadolinium in MRI and MRA with the development of nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy ('NSF/NSD'). NSF/NSD is characterized by tight, rigid skin that renders bending of the joints difficult, and fibrosis that may lead to multiorgan failure and death.

If you have been diagnosed with NSF/NSD, please contact our firm as soon as possible using the form below, or by calling our office at 1-866-653-7777, or by e-mail to Tim Turple or Mike Mantyka.

IF YOU WISH TO JOIN THE CLASS ACTION OR TO SIMPLY GET MORE INFORMATION, PLEASE COMPLETE THE FORM BELOW OR CALL US AT 1-866-653-7777. OR E-MAIL US AT TTURPLE@MERCHANTLAW.COM OR MMANTYKA@MERCHANTLAW.COM (Please note, providing your information creates no financial obligation for you. You are not charged any fee or cost for joining this class action - we are simply paid a contingency fee from the compensation recovered, if successful.)

POUR LE SERVICE EN FRANCAIS AU SUJET DE CE RECOURS COLLECTIF (OU D'AUTRE RECOURS POTENTIEL), S.V.P. CONTACTER NOTRE BUREAU DE MONTREAL: MONTREAL@MERCHANTLAW.COM.